TY - JOUR
T1 - Follicular lymphoma
T2 - Expanding therapeutic options
AU - Ganti, Apar Kishor
AU - Bociek, R. Gregory
AU - Bierman, Philip J.
AU - Enke, Charles A.
AU - Vose, Julie M.
AU - Armitage, James O.
PY - 2005
Y1 - 2005
N2 - The most common indolent lymphoma, follicular lymphoma comprises 35% of adult non-Hodgkin's lymphoma (NHL) in the United States and 22% worldwide. Features associated with adverse outcome include age, male gender, disease stage, and performance status, with the International Prognostic Index being the most widely used risk classification system. Long-term disease-free survival is possible in select patient subgroups after treatment, but very late relapses suggest that quiescent lymphoma cells might be harbored for long periods of time. Radiation therapy is the mainstay of treatment for limited-stage follicular lymphoma, but there is some experience with chemotherapy and combined chemoradiation. When to initiate treatment in patients with advanced disease is controversial, but options include various combined chemotherapy regimens, monoclonal antibodies, radiolabeled antibodies, and bone marrow or stem cell transplantation. Future directions in the treatment of follicular lymphoma include vaccines, antisense therapy, andproteasome inhibitors.
AB - The most common indolent lymphoma, follicular lymphoma comprises 35% of adult non-Hodgkin's lymphoma (NHL) in the United States and 22% worldwide. Features associated with adverse outcome include age, male gender, disease stage, and performance status, with the International Prognostic Index being the most widely used risk classification system. Long-term disease-free survival is possible in select patient subgroups after treatment, but very late relapses suggest that quiescent lymphoma cells might be harbored for long periods of time. Radiation therapy is the mainstay of treatment for limited-stage follicular lymphoma, but there is some experience with chemotherapy and combined chemoradiation. When to initiate treatment in patients with advanced disease is controversial, but options include various combined chemotherapy regimens, monoclonal antibodies, radiolabeled antibodies, and bone marrow or stem cell transplantation. Future directions in the treatment of follicular lymphoma include vaccines, antisense therapy, andproteasome inhibitors.
UR - http://www.scopus.com/inward/record.url?scp=19444375314&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=19444375314&partnerID=8YFLogxK
M3 - Review article
C2 - 15770890
AN - SCOPUS:19444375314
SN - 0890-9091
VL - 19
SP - 213
EP - 228
JO - ONCOLOGY
JF - ONCOLOGY
IS - 2
ER -